Ekberg M, Denneberg T, Larsson S, Juhlin I
Scand J Infect Dis. 1978;10(2):127-33. doi: 10.3109/inf.1978.10.issue-2.06.
Pivmecillinam which is the oral form of mecillinam was evaluated by treatment of 26 patients presenting various types of urinary tract infections and by prophylactic treatment of 12 patients. Pivmecillinam given in a daily dosage of 1.2 g for periods of 1 to 56 weeks was well tolerated in all of the patients including those with impaired renal function without any dose reduction. The original bacterial strain in the urine was eradicated in 100% of the cases. Two patients had a superinfection and 4 had a recurrence during a 3-month follow-up period. The oral absorption of pivmecillinam was investigated in 15 patients with normal or slightly reduced renal function and in 5 patients on maintenance hemodialysis. High serum levels were achieved within 1 to 2 h after administration. Patients with reduced renal function showed retarded elimination rates, suggesting that the dose should be adjusted in this category of patients.
匹美西林（美西林的口服形式）在26例患有各种类型尿路感染的患者治疗及12例患者的预防性治疗中进行了评估。匹美西林每日剂量为1.2 g，疗程1至56周，所有患者包括肾功能受损患者在未减少任何剂量的情况下耐受性良好。尿液中的原始菌株在100%的病例中被根除。在3个月的随访期内，2例患者发生了二重感染，4例患者复发。对15例肾功能正常或轻度减退的患者以及5例维持性血液透析患者进行了匹美西林口服吸收情况的研究。给药后1至2小时内达到高血清水平。肾功能减退的患者消除速率减慢，提示该类患者应调整剂量。
